EPHX2 and hyperuricemia: The research results suggest that the therapeutic effect of dioscin on plateau hyperuricemia may be achieved by its active metabolite diosgenin regulating the EPHX2 gene to regulate kidney lipid metabolism, alleviating kidney lipid accumulation, thereby reducing kidney inflammatory damage, producing a kidney-protective effect, and increasing the kidneys’ excretion of uric acid.